Hearticellgram-AMI
Phase 3Biologic
Hearticellgram-AMI is one of 38 biologic programs targeting Acute Myocardial Infarction. It is currently in Phase 3.
1
Indications
2
Total Trials
1
Active Trials
37
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
216 competitors in Acute Myocardial Infarction
#DrugCompanyPhaseTrials
1Farxiga
AstraZenecaPhase 3
Adenocard
AstellasPhase 3
Lovenox
SanofiPhase 3
Byetta
AstraZenecaPhase 3
Kineret
SSwedish Orphan Biovitrum
Phase 3
Jardiance
Boehringer IngelheimPhase 3
Neupogen
EEastern Cooperative Oncology Group
Phase 3
Reopro
Boehringer IngelheimPhase 3
Glucophage
EMD SeronoPhase 3
Xarelto
WWim Janssens
Phase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Hearticellgram-AMI. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Biologic[2]
- Highest Phase
- Phase 3[1]
- Company
- PPharmicell Co., Ltd.